Cyclophosphamide Injection, Powder, For Solution
Product Images NDC 10019-942

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Cyclophosphamide (NDC 10019-942). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cyclophosphamide Structural Formula (Image 01)

Chemical structure of cyclophosphamide showing a heterocyclic ring with phosphorus, nitrogen, and oxygen atoms, alongside the molecular groups including a chloroethyl, amide, and hydrate (H2O) component.*

FDA Label Image

Representative Cyclophosphamide Novaplus Container Label Ndc 10019-938-25 (Image 02)

Cyclophosphamide 500 mg/vial injection powder label by Baxter Healthcare Company. The label states it is for intravenous and oral use, sterile, non-pyrogenic, cytotoxic, single dose only. Instructions note dissolving with 25 mL sterile water for IV infusion or 0.9% sodium chloride for direct injection. Storage at or below 25°C is advised. Lot and NDC information are visible.*

FDA Label Image

Cyclophosphamide Novaplus Representative Carton Label Panel 1 Ndc 10019-938-01 (Image 03)

Packaging label for Cyclophosphamide for Injection, USP, 500 mg per vial. The label specifies it is for intravenous infusion or direct injection, single dose vial, and must be diluted before use. Manufactured by Baxter Healthcare Corporation, Deerfield, IL, and bearing the NOVAPLUS trademark. The label provides storage instructions, usage directions, and cautions that it is a cytotoxic agent for parenteral use.*

FDA Label Image

Cyclophosphamide Novaplus Representative Carton Label Panel 2 Ndc 10019-938-01 (Image 04)

The image shows the packaging label for Cyclophosphamide for Injection, USP, 500 mg/vial, manufactured by Baxter Healthcare Corporation. It is a single-dose vial requiring dilution for IV infusion or direct injection. The label includes NDC 10019-938-01, Novaplus branding, and states the product is made in Germany.*

FDA Label Image

Cyclophosphamide Novaplus Representative Container Ndc 10019-939-50 (Image 05)

Cyclophosphamide for Injection, USP 1 gram per vial powder for solution, labeled as a cytotoxic agent for single dose use, sterile, non-pyrogenic for parenteral administration. Manufactured by Baxter Healthcare Company, made in Germany. Instructions for IV infusion and direct injection use are included on the label.*

FDA Label Image

Cyclophosphamide Novaplus Representative Carton Label 10019-939-01 1 Of 2 (Image 06)

Packaging label for Cyclophosphamide Injection, USP 1 gram per vial, powder for solution. The label includes instructions indicating the vial must be diluted for IV infusion or direct injection use. Manufactured by Baxter Healthcare Corporation, the label also highlights that this is a single dose vial and a cytotoxic agent for sterile, non-pyrogenic parenteral use. Directions for dilution and storage information are included.*

FDA Label Image

Cyclophosphamide Novaplus Representative Carton Label 10019-939-01 2 Of 2 (Image 07)

Label for Cyclophosphamide for Injection, USP 1 gram per vial powder for solution. The label indicates it is for intravenous infusion or direct injection use and must be diluted. Manufactured by Baxter Healthcare Corporation, with trademarks NOVAPLUS and N+, and made in Germany. Includes NDC 10019-939-01 and a barcode.*

FDA Label Image

Cyclophosphamide Novaplus Representative Container Label 10019-942-10 (Image 08)

Label for Cyclophosphamide injection, USP, 2 gram per vial, a cytotoxic agent for single dose use. The vial contains 2 g cyclophosphamide powder for solution, intended for intravenous or oral administration. Manufactured by Baxter Healthcare Corporation, with usage instructions for dilution with sterile water or sodium chloride injection. The label includes storage instructions to keep the vial at or below 25°C (77°F).*

FDA Label Image

Cyclophosphamide Novaplus Representative Carton Label 10019-942-01 1 Of 2 (Image 09)

The carton label for Cyclophosphamide for Injection, USP, 2 gram per vial, manufactured by Baxter Healthcare Company. The label states the product is for intravenous or direct injection use, must be diluted, and is for single-dose use only. It includes handling instructions, storage conditions, and warnings about cytotoxicity. The label also features the NOVAPLUS logo and indicates the product is made in Germany.*

FDA Label Image

Cyclophosphamide Novaplus Representative Carton Label 10019-942-01 2 Of 2 (Image 10)

Label for Cyclophosphamide for Injection, USP 2 gram per vial, a powder for solution manufactured by Baxter Healthcare Corporation. The label specifies the product is Rx only, must be diluted for IV infusion or direct injection use, and is a single-dose vial. It also features NOVAPLUS branding and includes manufacturing details indicating it is made in Germany.*

FDA Label Image

Cyclophosphamide Representative Label 10019-938-01 1 Of 2 (Image 11)

Packaging label for NOVAPLUS Cyclophosphamide for Injection USP 500 mg. It indicates 120 packs each containing 1 vial of 500 mg single dose. Manufactured by Baxter Healthcare Corporation, the label includes storage instructions, lot and expiration placeholders, barcodes, and the NDC 10019-938-01.*

FDA Label Image

Cyclophosphamide Representative Label 10019-938-01 2 Of 2 (Image 12)

NOVAPLUS Cyclophosphamide for Injection, USP 500 mg powder for solution label. It indicates storage at or below 25°C, packaging of 120 single dose vials each containing 500 mg. Manufactured by Baxter Healthcare Company. The label includes an NDC code 10019-938-01, lot, expiration placeholders, and barcodes.*

FDA Label Image

Cyclophosphamide Representative Label 10019-939-01 1 Of 2 (Image 13)

Label for NOVAPLUS Cyclophosphamide for Injection, USP 1 g by Baxter Healthcare Company. The label indicates 120 packs, each containing 1 x 1 g single dose vials. Storage instructions specify keeping at or below 25°C (77°F). The label includes NDC 10019-939-01 and barcode information.*

FDA Label Image

Cyclophosphamide Representative Label 10019-939-01 2 Of 2 (Image 14)

Label for NOVAPLUS Cyclophosphamide for Injection, USP 1 g, a powder for solution in single dose vials. The label indicates storage at or below 25°C (77°F), contains 120 packs each with 1 vial, and is manufactured by Baxter Healthcare Corporation. The NDC is 10019-939-01.*

FDA Label Image

Cyclophosphamide Representative Label 10019-942-01 1 Of 2 (Image 15)

Packaging label for NOVAPLUS Cyclophosphamide for Injection, USP 2 g, supplied by Baxter Healthcare Company. The label indicates 60 packs, each containing 1 x 2 g single-dose vials. Storage instructions specify keeping at or below 25°C (77°F). The label includes an NDC number 10019-942-01 along with barcodes and manufacturing details from Baxter Healthcare Corporation, Deerfield, IL.*

FDA Label Image

Cyclophosphamide Representative Label 10019-942-01 2 Of 2 (Image 16)

NOVAPLUS Cyclophosphamide for Injection, USP 2 g vial label. The label includes storage instructions at or below 25°C, NDC 10019-942-01, and packaging details of 60 packs each containing one 2 g single-dose vial. Manufactured by Baxter Healthcare Corporation, Deerfield, IL, USA. Features barcode and lot and expiration date placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.